Description

5-Heptenoic Acid, 7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-Hydroxy-5-Phenylpentyl]Cyclopentyl]-, Methyl Ester, (5Z)- is a high-purity, stereochemically defined prostaglandin intermediate of significant synthetic importance. This compound serves as a critical chiral building block for the synthesis of complex bioactive molecules, particularly in advanced pharmaceutical research and development. It is essential for medicinal chemists and process development scientists working on prostaglandin analogs and other lipid-based therapeutics.

Application

• Pharmaceutical Intermediate: A key chiral synthon for the synthesis of prostaglandin and prostacyclin analogs, which are vital for drug discovery targeting cardiovascular, ocular, and inflammatory conditions.
• Medicinal Chemistry Research: Used in structure-activity relationship (SAR) studies to develop novel therapeutic agents with improved efficacy and selectivity.
• Process Chemistry & Scale-up: Employed in the development and optimization of scalable synthetic routes for active pharmaceutical ingredients (APIs) in a GMP environment.
• Biochemical Research: Utilized as a standard or probe in studies investigating eicosanoid signaling pathways and receptor interactions.
• Advanced Organic Synthesis: Serves as a versatile precursor for the construction of complex natural products and specialty chemicals with multiple stereocenters.

Basic Information

Product Name	5-Heptenoic Acid, 7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-Hydroxy-5-Phenylpentyl]Cyclopentyl]-, Methyl Ester, (5Z)-
CAS No.	913258-31-8
Molecular Formula	C25H36O5
Molecular Weight	416.55 g/mol
Synonyms	(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-Hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic Acid Methyl Ester; Methyl (5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; Prostaglandin F2α Methyl Ester Intermediate; 9,11,15-Trihydroxy-17-phenyl-18,19,20-trinorprosta-5,13-dien-1-oic Acid Methyl Ester (stereospecific); PGF2α Methyl Ester Synthon; 15(S)-15-Methyl-PGF2α Methyl Ester Precursor; Bimatoprost Advanced Intermediate; Travoprost Synthetic Intermediate
EINECS	Contact for details

Quality Control

Our production of this advanced pharmaceutical intermediate adheres to stringent quality systems. Each batch is manufactured under controlled conditions and undergoes comprehensive analytical testing, including chiral HPLC and NMR, to ensure high stereochemical purity and chemical identity. Certificates of Analysis (COA) detailing purity, enantiomeric excess, and impurity profiles are provided and can be tailored to meet specific client or regulatory requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at 2-8°C. This product is hygroscopic (moisture-sensitive) and should be handled under an inert atmosphere (e.g., nitrogen or argon) when opened for prolonged use to prevent degradation.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Identification (HPLC)	Conforms to reference standard
Assay (HPLC)	≥ 98.0%
Enantiomeric Excess (Chiral HPLC)	≥ 99.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Water Content (KF)	≤ 0.5%
Residual Solvents (GC)	Meets ICH Q3C guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.